News | Radiology Business | January 08, 2018

Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.

Name change completes Toshiba’s transition to Canon Group begun in December 2016

Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.

January 8, 2018 — Canon Inc. and Canon Medical Systems Corp. announced the official corporate name change of Canon Group Company Toshiba Medical Systems Corp. to Canon Medical Systems Corp. (hereafter referred to as Canon Medical Systems).

Since joining the Canon Group in December 2016, Canon Medical Systems has been undertaking the procedures for obtaining regulatory approval for integration with the Canon Group and change of the company name under the relevant national or regional laws concerning pharmaceuticals and medical devices. Canon announced that such procedures have been completed, and that the change of the company name entered into effect as of Jan. 4, 2018.

Through its integration with the Canon Group, Canon Medical Systems will continue to expand in order to accelerate the growth of the Canon Group’s medical equipment business throughout the world.

Canon Group was selected as the winning bidder for the acquisition of Canon Medical Systems in March 2016, with a bid reportedly valued at $6.21 billion.

Canon Medical Systems USA Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including computed tomography (CT), magnetic resonance imaging (MRI) ultrasound, X-ray and interventional X-ray equipment.

Read the article "Canon to Acquire Toshiba Medical"

For more information: www.us.medical.canon

Related Content

Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne